The prices of new life-saving medicines have never been so high in the EU, putting our social security models, universal rights to care-access and national budgets at risk. Poor countries don't have the monopoly of care exclusion anymore. Who is responsible for this situation? More and more stakeholders point at our broken R&D model in the pharmaceutical sector: less real and needed innovation, less return on investment for publicly funded research because of private patenting and privatized benefits, more short-term pressure from the shareholders in the care sector. So what can be done at EU level?
↧